Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%

References

• Hovding G. Acute bacterial conjunctivitis. Acta Ophthalmol. 2008;86:5–17. doi:10.1111/j.1600-0420.2007.01006.x
   PubMed Web of Science ®Google Scholar
• Block SL, Hedrick J, Tyler R, et al. Increasing bacterial resistance in pediatric acute conjunctivitis (1997–1998). Antimicrob Agents Chemother. 2000;44:1650–1654. doi:10.1128/AAC.44.6.1650-1654.2000
   PubMed Web of Science ®Google Scholar
• Buznach N, Dagan R, Greenberg D. Clinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance era. Pediatr Infect Dis J. 2005;24:823–828. doi:10.1097/01.inf.0000178066.24569.98
   PubMed Web of Science ®Google Scholar
• Weiss A, Brinser JH, Nazar-Stewart V. Acute conjunctivitis in childhood. J Pediatr. 1993;122(1):10–14. doi:10.1016/S0022-3476(05)83479-1
   PubMed Web of Science ®Google Scholar
• Azari AA, Barney NP. Conjunctivitis: a systematic review of diagnosis and treatment. JAMA. 2013;310(16):1721–1729. doi:10.1001/jama.2013.280318
   PubMed Web of Science ®Google Scholar
• Kunimoto DY, Das T, Sharma S, et al.; Endophthalmitis Research Group. Microbiologic spectrum and susceptibility of isolates: part I. Postoperative endophthalmitis. Am J Ophthalmol. 1999;128(2):240–242. doi:10.1016/S0002-9394(99)00112-9
   PubMed Web of Science ®Google Scholar
• Kunimoto DY, Das T, Sharma S, et al.; Endophthalmitis Research Group. Microbiologic spectrum and susceptibility of isolates: part II. Posttraumatic endophthalmitis. Am J Ophthalmol. 1999;128(2):242–244. doi:10.1016/S0002-9394(99)00113-0
   PubMed Web of Science ®Google Scholar
• Bourcier T, Thomas F, Borderie V, Chaumeil C, Laroche L. Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol. 2003;87(7):834–838. doi:10.1136/bjo.87.7.834
   PubMed Web of Science ®Google Scholar
• Lim NC, Lim DK, Ray M. Polymicrobial versus monomicrobial keratitis: a retrospective comparative study. Eye Contact Lens. 2013;39(5):348–354. doi:10.1097/ICL.0b013e3182a3024e
   Web of Science ®Google Scholar
• Hooi SH, Hooi ST. Culture-proven bacterial keratitis in a Malaysian general hospital. Med J Malaysia. 2005;60(5):614–623.
   Google Scholar
• Stefan C, Nenciu A. Post-traumatic bacterial keratitis—a microbiological prospective clinical study. Oftalmologia. 2006;50(3):118–122.
   Google Scholar
• Preechawat P, Ratananikom U, Lerdvitayasakul R, Kunavisarut S. Contact lens-related microbial keratitis. J Med Assoc Thai. 2007;90(4):737–743.
   Google Scholar
• Termote K, Joe AW, Butler AL, et al. Epidemiology of bacterial corneal ulcers at tertiary centres in Vancouver, B.C. Can J Ophthalmol. 2018;53(4):330–336. doi:10.1016/j.jcjo.2017.11.001
   Web of Science ®Google Scholar
• Sowmya P, Madhavan HN. Diagnostic utility of polymerase chain reaction on intraocular specimens to establish the etiology of infectious endophthalmitis. Eur J Ophthalmol. 2009;19(5):812–817. doi:10.1177/112067210901900520
   PubMed Web of Science ®Google Scholar
• Pijl BJ, Theelen T, Tilanus MA, Rentenaar R, Crama N. Acute endophthalmitis after cataract surgery: 250 consecutive cases treated at a tertiary referral center in the Netherlands. Am J Ophthalmol. 2010;149(3):482–487.e1–2. doi:10.1016/j.ajo.2009.09.021
   Web of Science ®Google Scholar
• Bhattacharjee H, Bhattacharjee K, Gogoi K, Singh M, Singla BG, Yadav A. Microbial profile of the vitreous aspirates in culture proven exogenous endophthalmitis: a 10-year retrospective study. Indian J Med Microbiol. 2016;34(2):153–158. doi:10.4103/0255-0857.180280
   PubMed Web of Science ®Google Scholar
• Wong T, Ormonde S, Gamble C, McGhee CNJ. Severe infective keratitis leading to hospital admission in New Zealand. Br J Ophthalmol. 2003;87(9):1103–1108. doi:10.1136/bjo.87.9.1103
   Web of Science ®Google Scholar
• DeCory HH, Sanfilippo CM, Proskin HM, Blondeau JM. Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6%. PLoS One. 2020;15(8):e0237603. doi:10.1371/journal.pone.0237603
   Web of Science ®Google Scholar
• Bhattacharyya A, Sarma P, Sarma B, et al. Bacteriological pattern and their correlation with complications in culture positive cases of acute bacterial conjunctivitis in a tertiary care hospital of upper Assam: a cross sectional study. Medicine (Baltimore). 2020;99(7):e18570. doi:10.1097/MD.0000000000018570
   Web of Science ®Google Scholar
• Hashish AA, Elbakary MA, Allam WA. Resistant infantile bacterial conjunctivitis in Egypt: a microbiology study. J Pediatr Ophthalmol Strabismus. 2018;55(2):135–139. doi:10.3928/01913913-20170718-01
   Web of Science ®Google Scholar
• Rose PW, Harnden A, Brueggemann AB, et al. Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial. Lancet. 2005;366(9479):37–43. doi:10.1016/S0140-6736(05)66709-8
   Web of Science ®Google Scholar
• Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25(5):1159–1169. doi:10.1185/03007990902837919
   PubMed Web of Science ®Google Scholar
• McDonald MB, Protzko EE, Brunner LS, et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 2009;116(9):1615–1623.e1. doi:10.1016/j.ophtha.2009.05.014
   Web of Science ®Google Scholar
• Karpecki P, Depaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009;31(3):514–526. doi:10.1016/j.clinthera.2009.03.010
   Web of Science ®Google Scholar
• DeLeon J, Silverstein BE, Allaire C, et al. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children. Clin Drug Investig. 2012;32(5):303–317. doi:10.2165/11632470-000000000-00000
   Web of Science ®Google Scholar
• Malhotra R, Ackerman S, Gearinger LS, Morris TW, Allaire C. The safety of besifloxacin ophthalmic suspension 0.6% used three times daily for 7 days in the treatment of bacterial conjunctivitis. Drugs R D. 2013;13(4):243–252. doi:10.1007/s40268-013-0029-1
   Google Scholar
• Haas W, Gearinger LS, Usner DW, Decory HH, Morris TW. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clin Ophthalmol. 2011;5:1369–1379. doi:10.2147/OPTH.S23519
   PubMedGoogle Scholar
• Cagle G, Davis S, Rosenthal A, Smith J. Topical tobramycin and gentamicin sulfate in the treatment of ocular infections: multicenter study. Curr Eye Res. 1981;1(9):523–534. doi:10.3109/02713688109069178
   Web of Science ®Google Scholar
• Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol. 1991;112(Suppl4):29S–33S.
   Google Scholar
• Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standards. 6th ed. In: CLSI Document M07-A6. Wayne, PA: Clinical and Laboratory Standards Institute; 2003.
   Google Scholar
• Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standards. 7th ed. In: CLSI Document M07-A7. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
   Google Scholar
• Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard. 8th ed. In: CLSI Document M07-A8. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
   Google Scholar
• Rasmussen LH, Højholt K, Dargis R, et al. In silico assessment of virulence factors in strains of Streptococcus oralis and Streptococcus mitis isolated from patients with Infective Endocarditis. J Med Microbiol. 2017;66(9):1316–1323. doi:10.1099/jmm.0.000573
   Web of Science ®Google Scholar
• Mitchell J. Streptococcus mitis: walking the line between commensalism and pathogenesis. Mol Oral Microbiol. 2011;26(2):89–98. doi:10.1111/j.2041-1014.2010.00601.x
   Web of Science ®Google Scholar
• Bair KL, Campagnari AA. Moraxella catarrhalis promotes stable polymicrobial biofilms with the major otopathogens. Front Microbiol. 2020;10:3006. doi:10.3389/fmicb.2019.03006
   PubMed Web of Science ®Google Scholar
• Perez AC, Pang B, King LB, et al. Residence of Streptococcus pneumoniae and Moraxella catarrhalis within polymicrobial biofilm promotes antibiotic resistance and bacterial persistence in vivo. Pathog Dis. 2014;70(3):280–288. doi:10.1111/2049-632X.12129
   PubMed Web of Science ®Google Scholar
• Short FL, Murdoch SL, Ryan RP. Polybacterial human disease: the ills of social networking. Trends Microbiol. 2014;22(9):508–516. doi:10.1016/j.tim.2014.05.007
   Web of Science ®Google Scholar
• Brogden KA, Guthmiller JM, Taylor CE. Human polymicrobial infections. Lancet. 2005;365:253–255. doi:10.1016/S0140-6736(05)70155-0
   PubMed Web of Science ®Google Scholar
• Griffiths EC, Pedersen AB, Fenton A, Petchey OL. The nature and consequences of coinfection in humans. J Infect. 2011;63(3):200–206. doi:10.1016/j.jinf.2011.06.005
   PubMed Web of Science ®Google Scholar
• Silvester A, Neal T, Czanner G, Briggs M, Harding S, Kaye S. Adult bacterial conjunctivitis: resistance patterns over 12 years in patients attending a large primary eye care centre in the UK. BMJ Open Ophthalmol. 2016;1(1):e000006. doi:10.1136/bmjophth-2016-000006
   Google Scholar
• Shrestha SP, Khadka J, Pokhrel AK, Sathian B. Acute bacterial conjunctivitis—antibiotic susceptibility and resistance to commercially available topical antibiotics in Nepal. Nepal J Ophthalmol. 2016;8(15):23–35. doi:10.3126/nepjoph.v8i1.16153
   Google Scholar
• Asbell PA, DeCory HH. Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. PLoS One. 2018;13(10):e0205814. doi:10.1371/journal.pone.0205814
   Web of Science ®Google Scholar
• Alter SJ, Sanfilippo CM, Asbell PA, DeCory HH. Antibiotic resistance among pediatric-sourced ocular pathogens: 8-year findings from the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. Pediatr Infect Dis J. 2019;38:138–145. doi:10.1097/INF.0000000000002206
   Web of Science ®Google Scholar
• Asbell PA, Sanfilippo CM, Sahm DF, DeCory HH. Trends in antibiotic resistance among ocular microorganisms in the United States from 2009 to 2018. JAMA Ophthalmol. 2020;138(5):1–12. doi:10.1001/jamaophthalmol.2020.0155
   Web of Science ®Google Scholar
• Research and Markets. Global conjunctivitis drugs market 2018–2024. Available from: https://www.researchandmarkets.com/research/xx9d9p/global?w=5. Accessed December 8, 2020.
   Google Scholar
• Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009;53(8):3552–3560. doi:10.1128/AAC.00418-09
   Web of Science ®Google Scholar
• Haas W, Pillar CM, Hesje CK, Sanfilippo CM, Morris TW. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother. 2010;65(7):1441–1447. doi:10.1093/jac/dkq127
   Web of Science ®Google Scholar
• Haas W, Sanfilippo CM, Hesje CK, Morris TW. Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones. Clin Ophthalmol. 2013;7:821–830. doi:10.2147/OPTH.S44085
   PubMedGoogle Scholar
• Miller D, Chang JS, Flynn HW, Alfonso EC. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci. J Ocul Pharmacol Ther. 2013;29(3):339–344. doi:10.1089/jop.2012.0081
   Web of Science ®Google Scholar
• Cambau E, Matrat S, Pan XS, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 2009;63(3):443–450. doi:10.1093/jac/dkn528
   Web of Science ®Google Scholar
• Mah FS, Sanfilippo CM. Besifloxacin: efficacy and safety in treatment and prevention of ocular bacterial infections. Ophthalmol Ther. 2016;5:1–20. doi:10.1007/s40123-016-0046-6
   PubMed Web of Science ®Google Scholar
• Murray JL, Connell JL, Stacy A, Turner KH, Whiteley M. Mechanisms of synergy in polymicrobial infections. J Microbiol. 2014;52(3):188–199. doi:10.1007/s12275-014-4067-3
   Web of Science ®Google Scholar
• Hendricks KJ, Burd TA, Anglen JO, Simpson AW, Christensen GD, Gainor BJ. Synergy between Staphylococcus aureus and Pseudomonas aeruginosa in a rat model of complex orthopaedic wounds. J Bone Joint Surg Am. 2001;83(6):855–861. doi:10.2106/00004623-200106000-00006
   Web of Science ®Google Scholar
• Bousbia S, Raoult D, La Scola B. Pneumonia pathogen detection and microbial interactions in polymicrobial episodes. Future Microbiol. 2013;8(5):633–660. doi:10.2217/fmb.13.26
   Web of Science ®Google Scholar
• Shak JR, Vidal JE, Klugman KP. Influence of bacterial interactions on pneumococcal colonization of the nasopharynx. Trends Microbiol. 2013;21(3):129–135. doi:10.1016/j.tim.2012.11.005
   PubMed Web of Science ®Google Scholar
• Nguyen AT, Oglesby-Sherrouse AG. Interactions between Pseudomonas aeruginosa and Staphylococcus aureus during co-cultivations and polymicrobial infections. Appl Microbiol Biotechnol. 2016;100(14):6141–6148. doi:10.1007/s00253-016-7596-3
   PubMed Web of Science ®Google Scholar
• Catalanotti P, Lanza M, Del Prete A, et al. Staphylococcus epidermidis and S. aureus in acute bacterial conjunctivitis in soft contact lens wearers. New Microbiol. 2005;28(4):345–454.
   Web of Science ®Google Scholar
• Murugan K, Usha M, Malathi P, Al-Sohaibani AS, Chandrasekaran M. Biofilm forming multi drug resistant Staphylococcus spp. among patients with conjunctivitis. Pol J Microbiol. 2010;59(4):233–239. doi:10.33073/pjm-2010-036
   Web of Science ®Google Scholar
• Flores-Páez LA, Zenteno JC, Alcántar-Curiel MD, et al. Molecular and phenotypic characterization of Staphylococcus epidermidis isolates from healthy conjunctiva and a comparative analysis with isolates from ocular infection. PLoS One. 2015;10(8):e0135964. doi:10.1371/journal.pone.0135964
   Web of Science ®Google Scholar
• Fariña N, Samudio M, Carpinelli L, Nentwich MM, de Kaspar HM. Methicillin resistance and biofilm production of Staphylococcus epidermidis isolates from infectious and normal flora conjunctiva. Int Ophthalmol. 2017;37(4):819–825. doi:10.1007/s10792-016-0339-8
   Web of Science ®Google Scholar
• Elkhashab THT, Adel LA, Nour MS, Mahran M, Elkaffas M. Association of intercellular adhesion gene A with biofilm formation in staphylococci isolates from patients with conjunctivitis. J Lab Physicians. 2018;10(3):309–315. doi:10.4103/JLP.JLP_122_17
   Web of Science ®Google Scholar